Last reviewed · How we verify
NCT03126487: MRHEATBREAST
High Intensity Focused Ultrasound Guided by MRI as Thermic Destruction in Primitive Small Size Breast Cancer
NA trial testing HIGH INTENSITY FOCUSED ULTRASOUND in Breast Cancer. Withdrawn.
11 January 2018
Quick facts
| Lead sponsor | Centre Antoine Lacassagne |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 25 April 2017 |
| Primary completion | 11 January 2018 |
| Estimated completion | 11 January 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- HIGH INTENSITY FOCUSED ULTRASOUND
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Centre Antoine Lacassagne — full company profile →
Who can join
19 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a non-randomized, prospective phase II trial evaluating an innovative treatment, focused MRI-guided ultrasound, as thermic destruction in primitive small size breast cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03126487
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Centre Antoine Lacassagne trials
Trials by the same sponsor.
- NCT07429487 — Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fati · NA · not yet recruiting
- NCT06782451 — Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity · NA · recruiting
- NCT06606366 — Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplina · NA · recruiting
- NCT06400849 — Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy · NA · recruiting
- NCT06029218 — Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03126487 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Antoine Lacassagne
- Last refreshed: 29 January 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03126487.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing